FDA approves new treatment for metastatic triple-negative breast cancer
Full article:

The FDA approved the use of sacituzumab govitecan-hizy (Trodelvy), a treatment drug for people with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. (4/27/20)

Expert Guidelines

The FDA approved Troveldy to treat metastatic TNBC in people who have had at least two prior lines of treatment. 

The National Comprehensive Cancer Network (NCCN) is a national panel of experts that creates guidelines for cancer treatment. NCCN recommends the following testing for targeted therapy in people with metastatic TNBC:

Questions To Ask Your Health Care Provider

Open Clinical Trials


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.